Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
CPF honors three critical areas of leadership for Pulmonary Fibrosis community

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

Volunteers, families in IL, IN, NY, and PA unite to raise money and awareness about pulmonary fibrosis

Volunteers, families in IL, IN, NY, and PA unite to raise money and awareness about pulmonary fibrosis

Amira submits IND application for AM152 antagonist

Amira submits IND application for AM152 antagonist

New federal funds to create first national patient registry for pulmonary fibrosis

New federal funds to create first national patient registry for pulmonary fibrosis

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Fundraising events in September in support of pulmonary fibrosis research

Fundraising events in September in support of pulmonary fibrosis research

Stromedix's STX-100 receives orphan drug status from FDA for treatment of IPF

Stromedix's STX-100 receives orphan drug status from FDA for treatment of IPF

PFF announces $400,000 grant for pulmonary fibrosis research

PFF announces $400,000 grant for pulmonary fibrosis research

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

CPF continues partnership with American Thoracic Society to fund Pulmonary Fibrosis research

CPF continues partnership with American Thoracic Society to fund Pulmonary Fibrosis research

Pulmonary Fibrosis Foundation to support 2010 National PF Week

Pulmonary Fibrosis Foundation to support 2010 National PF Week

CPF urges people to consider clinical trials for pulmonary fibrosis

CPF urges people to consider clinical trials for pulmonary fibrosis

PFF announces introduction of Pulmonary Fibrosis Research Enhancement Act in US Senate

PFF announces introduction of Pulmonary Fibrosis Research Enhancement Act in US Senate

CPF announces nationwide advertising campaign to increase awareness about PF

CPF announces nationwide advertising campaign to increase awareness about PF

Geron second-quarter net loss decreases to $17.0 million

Geron second-quarter net loss decreases to $17.0 million

Celgene second-quarter non-GAAP total revenue increases 36% to $850 million

Celgene second-quarter non-GAAP total revenue increases 36% to $850 million

InterMune second-quarter total revenue decreases to $5.9 million

InterMune second-quarter total revenue decreases to $5.9 million

Activities of TAT fully consolidated into Geron

Activities of TAT fully consolidated into Geron

FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations

FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.